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Abstract 
 
Background: Functional chemokine receptors are expressed in many 
malignant tumors, including papillary thyroid carcinoma (PTC). These 
receptors promote tumor growth and metastasis in response to endogenous 
chemokines. 
 The purpose of this study was to examine the expression of SDF-1 and its 
chemokine receptors, CXCR4, in a series of PTCs, considered as low risk for 
tumor size and hystotypes. 
 In this study, we correlated CXCR4 and SDF-1 with indicators of clinical and 
tumor aggressiveness, including age, gender, tumor size, extrathyroidal 
extension, multifocality and lymph node metastasis. 
Methods: CXCR4 as well as its specific chemokine ligand, SDF-1 , were 
assessed in 48 PTCs using a semiquantitative measure of 
immunohistochemical (IHC) staining intensity for each molecule. Staining 
intensity was compared with clinicopathological features. Expression in 
CXCR4 and SDF-1 mRNA levels were sought in a subset of tumors, using 
gene microarrays and quantitative RTPCR. 
Results: In 29 cases, the PTC was associated with chronic thyroiditis.  High-
intensity IHC staining for CXCR4 correleted with T1 (p=0.003), classical 
variant (p=0.02) and lymph node metastasis at initial diagnosis (p=0.01). In 
contrast SDF 1 correlated with  female gender (p =0.05), but this association 
was not shown following multivariate analyses.  
Conclusion: In our study,  the expression of CXCR4 and its ligand are more 
frequent in tumors that have a smaller dimension and a  classical variant of 
PTC. Therefore, CXCR4 and its ligand are associated with lymph node 
metastasis involvement at the initial diagnosis, which is an indicator of 
negative prognosis. Finally, the chemokine pathways may be expressed early in 
PTC tumorigenesis. Although these markers are found in a less aggressive PTC 
variant, they may be responsible for early and preferential lymphnode neck 
metastases.  Further studies are necessary to define the mechanisms underlying 
this association and to determine its potential prognostic and therapeutic 
implications. 
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1.Introduction 
 
Thyroid carcinoma accounts for roughly 1% of all new malignant diseases; 
about 0.5% of cancers in men and 1.5% in women.  Of these, about 94% are 
differentiated thyroid tumors that derive from the follicular epithelial cells, 
such as papillary and follicular thyroid carcinomas. Another 5% are  
medullary thyroid carcinoma, a neuroendocine tumor. The remaining 1% are 
anaplastic carcinoma that generally derive from dedifferentiation of the 
differentiated type. (Schlumberger 1998; Sherman, 2003)   
The incidence of thyroid cancer has been increasing in many countries over the 
last 30 years (from 3.6/100 000 people in 1973 to 8.7/100 000 people in 2002) 
while mortality has been slowly decreasing. The increase is attributable to 
better detection of small papillary carcinomas (PTC) as a result of improved 
diagnostic accuracy (neck ultrasound and fine needle aspiration cytology). In 
fact, nearly 60–80% of thyroid carcinomas detected nowadays are 
micropapillary thyroid carcinomas (<1 cm in size), carrying an excellent long-
term prognosis. (Davies L et al, 2006,  Pacini F et al  2008, ). Despite the 
generally favorable prognosis of these tumors with a 10-year survival rate 
exceeding 90%, the rates of locoregional and distant recurrences are as high as 
5.9% and 1.5%, respectevely, and cancer related mortality may be 1- 2%. 
Consequently, it is necessary to identify patients who have a risk of progressive 
disease at the time of diagnosis. The importance of recognizing prognostic 
variables is also relevant for the best management such as, the extent of thyroid 
surgery and the indications for post operative radioiodine therapy (Sugitani I et 
al, 1999, Mazzaferri EL 2007). A careful prognostic classification is also 
critical for the comparison of treatment results. Therefore, a reliable new 
prognostic classification is needed in PTC patients to modify initial therapy 
and follow up schemes to the risks of persistent or recurrent disease. 
Conventionally, patient age at diagnosis, gender, tumor size, extrathyroidal 
invasiveness, multifocality,  lymph node involvement at the initial diagnosis 
and certain histological markers are known to be associated with recurrence 
and poor prognosis (DeGroot LJ et al, 1990; Mazzaferri EL et al 1981).  
Moreover, lymphocytic infiltration is frequently observed in PTC, although 
there are few and conflicting reports concerning the association between the 
prognosis of PTC and the degree of lymphocytic infiltration surrounding and 
/or inside the tumor (Hirabayashi RN, et al 1965; Clark OH et al 1980; Aguayo 
J et al 1989; Matsubayashi et al 1995). 
Consequently,  three distinguishing features of PTC should be considered as  
the basis to formulate new criteria for the prognosis.  The first feature regards 
the activation of downstream signal transduction pathway and modulation of 
gene expression induced by RET/PTC. The second is a prominent peritumoral 
inflammatory reaction, which suggests cross-talk between tumor cells and the 
inflammatory system. Third, PTC is often characterized by early metastases 
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spread to regional lymph nodes and by multifocal involvement of the gland, 
which suggest highly invasive behavior. 
 
 
 
1.1 Papillary Thyroid Cancer (PTC): hystological variant and  molecular 
genetics 
 
Numerous variants of PTC are already known. The classical variant (45%) 
and the follicular variant (18%) are the most common and frequently  
diagnosed tumors.  The follicular variant  tumors may be encapsulated or non-
encapsulated and are composed almost exclusively of follicles having the 
characteristic nuclear features of PTC. Inter observation variation in the 
diagnosis of these tumors, particularly the encapsulated type, is high since the 
nuclear features may be focal or poorly developed. Lymph node metastases 
are less common in the follicular variant than in classical PTCs. 
Microfollicular, oncocytic, Warthin-like, and clear cell variants have a 
prognosis that is similar to conventional PTCs. The solid variant comprises 
approximately 8% of sporadic PTCs and is relatively common in children 
following radiation exposure. This variant is associated with a slightly higher 
frequency of distant metastases and a somewhat less favorable prognosis than 
conventional PTC. The diffuse sclerosing variant is more of pulmonary 
metastases than conventional PTCs although overall survivals do not differs 
have a worse prognosis than conventional PTCs; however, stage and grade 
may be more important than histological subtypes. The prognosis of PTCs 
with poorly differentiated, undifferentiated, or squamous carcinoma 
components depends on the proportion of the non-PTC component. The term 
papillary ‘‘microcarcinoma’’ is reserved for those tumors measuring less than 
1 cm in diameter. Although most of these tumors have follicular or papillary 
architectural features, any of the variants may measure less than 1 cm. 
Papillary microcarcinomas are extremely common, occurring in up to 30% of 
autopsies and in up to 24% of surgical thyroidectomies performed for 
disorders unrelated to PTC (Asklen LA et al 2000; Nikiforov YE et al 2001; 
Lloyd  et al 2004; Delellis R, 2006).  
Recent years have been marked by dramatic expansion in the understanding of 
the molecular basis of thyroid carcinogenesis. It has become apparent that 
thyroid tumors, especially those of the papillary type, frequently go through   
genetic alterations leading to the activation of the mitogenactivate protein 
kinase (MAPK) signaling pathway. This crucial intracellular cascade regulates 
cell growth, differentiation and survival in response to growth factors, 
hormones and cytokines that interact with receptor tyrosine kinases present on 
the cell surface (Fusco A et al 1987;  Grieco M et al 1990; Ciampi R, 2006; 
Santoro M et al 2006) (Fig. 1).  
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Fig. 1. Schematic representation of the mitogen-activated protein kinase (MAPK) signaling pathway. 
Physiologically, binding of growth factors to receptor tyrosine kinases, such RET and NTRK1, results in 
receptor dimerization and activation via autophosphorylation of tyrosine residues in the intracellular 
domain. The activated receptor, through a series of adaptor proteins, leads to activation of RAS located at 
the inner face of the plasma membrane by substitution of GDP with GTP. The GTP-bound form of RAS 
binds to and recruits RAF proteins, mainly BRAF in thyroid follicular cells, to the plasma membrane. 
Activated BRAF is now able to phosphorylate and activate the mitogen-activated protein kinase/ERK 
kinase (MEK), which in turn phosphorylates and activates the extracellular-signal-regulated kinase 
(ERK). Once activated, ERK phosphorylates cytoplasmic proteins and translocates into the nucleus, 
where it regulates transcription of the genes involved in cell differentiation, proliferation and survival. 
Alterations of this pathway in thyroid cancer can occur at different levels as a result of point mutation or 
rearrangement involving the RET, RAS, and BRAF genes. (Ciampi R and Nikiforov YE, 
Endocrinology  2006) 
 
 
 
 
Molecular alterations found in papillary carcinomas involve genes coding for 
the receptor tyrosine kinases RET and NTRK1, and for two intracellular 
effectors of the MAPK pathway, a GTP-binding protein RAS and a serine-
threonine kinase BRAF. Mutation of one of these genes can be found in more 
than 70% of papillary carcinomas and they rarely overlap in the same tumor, 
suggesting that activation of this signalling pathway is essential for tumor 
initiation and alteration of a single effector of the pathway is sufficient for cell 
transformation.  
Notably, in about 40-50% of papillary thyroid carcinomas the kinase domain 
of the tyrosine kinase receptor for the GDNF, c-Ret (REarranged during 
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Transfection), is fused with the N-terminal region of constitutively expressed, 
heterologous genes, such as H4 (in RET/PTC1) or RFG (in RET/PTC3). In 
RET/PTC rearrangements, fusion with protein partners, possessing protein-
protein interaction domains, provides RET/PTC proteins with coiled-coil 
domains, thereby resulting in ligand-independent activation of c-Ret tyrosine 
kinase activity (Santoro et al. 1995). Similar rearrangements of the high 
affinity receptor for NGF (Nerve Growth Factor), TRKA, can be also found, 
at a low prevalence (in about 10% of the tumors), in human PTC. RET 
activates many intracellular signaling pathways. Upon binding to ligand, it 
dimerizes and autophosphorylates various cytoplasmic tyrosines. The 
phosphorylated tyrosines thus become binding sites for intracellular molecules 
containing phosphotyrosine-binding motifs, thereby initiating a diverse array 
of signaling pathways (Santoro et al. 2004). In RET/PTC rearrangements, 
fusion with protein partners possessing coiled-coil domains provides 
RET/PTC kinases with dimerizing interfaces, thereby resulting in ligand-
independent autophosphorylation. The most common rearranged forms of 
RET are RET/PTC1 and RET/PTC3, resulting from paracentric inversions of 
the long arm of chromosome 10, and RET/PTC2, resulting from a 10; 17 
reciprocal translocation involving R1a on17q23. More than 11 additional 
types of RET rearrangements, occurring primarily in radiation-induced 
tumors, have been described but their frequencies are low. The role of 
RET/PTC in the development of PTC has been demonstrated convincingly in 
transgenic mice with targeted overexpression of RET/PTC1 and RET/PTC3. 
The RET/PTC1 rearrangement is more common in classic PTCs, papillary 
microcarcinomas, and the diffuse sclerosing variant than in other subtypes. 
RET/PTC3, on the other hand, has been associated with the solid variant. 
The RET intracellular domain contains at least 12 autophosphorylation sites, 
11 of which are maintained in RET/PTC proteins (Kawamoto et al. 2004). 
Tyr 905 is located in the activation loop and its phosphorylation stabilizes 
the enzyme in an active conformation. Moreover, when phosphorylated, Tyr 
905 binds some SH2- containing proteins, such as Grb7 and Grb10 (Pandey 
et al. 1996). Phosphorylated Tyr 1015 and Tyr 1096 are responsible for 
binding of PLCγand GRB2, respectively (Jhiang S.M. 2000; van Weering et 
al. 1998). Several protein adaptors, Shc, FRS2, IRS1/2, DOK1/4/5, 
RAI/NShc and Enigma recognize phosphorylated Tyr 1062 ( Lorenzo et al. 
1997, Pelicci et al. 2002, Melillo et al 2001).  
The multi-docking site Tyr1062, upon phosphorylation, is responsible for the 
activation of the phosphatidylinositol 3- kinase (PI3K)/AKT and the mitogen-
activated protein kinase (MAPK) pathways, the latter involving the 
extracellular-regulated kinase (ERKs), c-Jun amino-terminal protein kinase 
(JNKs) and the p38 MAPK (Jhiang S.M. 2000;  van Weering et al. 1998). 
Moreover,  RET/PTC induced the expression of a pro-inflammatory 
transcriptional program. Such a program included the up-regulation of various 
cytokines (OPN/SPP1, GM-CSF, M-CSF, G-CSF, IL1A, IL1B, IL6, and 
IL24), chemokines (CCL2, CCL20, CXCL8, CXCL1, CXCL10, and 
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CXCL12) chemokine receptors (CXCR4) pro-inflammatory enzymes 
(cyclooxygenase-2, and microsomal prostaglandin E2 synthase), and 
interferon-dependent genes. (fig 2) 
 
 
 
 
Fig 2.  Induction of an inflammatory-type reaction might be part of the oncogenic effect of RET/ PTC on 
thyroid cancer and may explain the chronic inflammatory reaction that is characteristic of this tumor type. 
(Borrello et al . PNAS 2005) 
 
 
 
By activating point mutations in RAS small GTPase are found roughly 
in 10% of PTC, mainly in those belonging to the follicular variant 
(PTC-FV) (Zhu et al. 2003). Point mutations in BRAF are the most 
common genetic lesion found in PTC (up to 50% of the cases) (Kimura 
et al. 2003; Xu et al. 2003). BRAF is a member of the RAF family of 
serine/threonine kinases and it is a component of the RAF-MEK-ERK 
signaling module. Activation of the RAF proteins is mediated through 
binding of RAS in its GTP-bound state. Once activated, RAF kinases 
phosphorylate MEK which in turn phosphorylates and activates ERK 
(Malumbres et al. 2003). A Glutamine for Valine substitution at residue 
600 (V600E) in the activation segment accounts for more than 90% 
mutations of BRAF in PTC. This mutation enhances BRAF activity 
through the disruption of the autoinhibited state of the kinase. In human 
PTCs the genetic alterations of RET/PTC, RAS and BRAF are mutually 
exclusive, suggesting the existence of a common signaling cascade; 
moreover, mutations at more than one of these sites are unlikely to 
provide an additional biological advantage (Kimura et al. 2003, Cohen 
et al. 2003, Soares et al. 2003).  
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1.2 The Correlation between Papillary Thyroid Carcinoma  and   
Inflammatory reaction  
. 
PTC is associated with a striking chronic inflammatory reaction in about 30% of 
cases, (Ott et al., 1987; Wirtschafter.et al., 1997; Mechler et al., 2001; Di 
Pasquale, 2001; Pisanu et al., 2003) in particular several observations suggest 
that the immune response might be important in preventing metastases and 
recurrence of thyroid cancer, 65% of PTC in children and young adults 
contained lymphocytes in the immediate vicinity of thyroid cancer, but only 
18% of patients also had a diagnosis of autoimmune thyroiditis . In these cases, 
the role in neoplastic transformation of the infiltrates of lymphocytes present in 
both autoimmune thyroid disease and PTC  is not yet clear; patients with 
Hashimoto thyroiditis and PTC have generally improved disease-free survival, 
while Graves disease is associated with worse prognosis.  
In particolar, Hashimoto thyroiditis is an autoimmune disorder in which the 
immune system reacts against a variety of thyroid antigens. The overriding 
feature of Hashimoto thyroiditis is the progressive depletion of thyroid 
epithelial cells (thyrocytes), which are gradually replaced by mononuclear cell 
infiltration and fibrosis. Multiple immunologic mechanisms may contribute to 
the death of thyrocytes. Sensitization of autoreactive CD4+ T-helper cells to 
thyroid antigens appears to be the initiating event. Hashimoto’s thyroiditis is 
characterized by proliferating nodules as well as cytological alterations and 
nuclear modifications similar to those of the papillary carcinomas (Sclafani et 
al., 1993;).  
Originally, the rearrangement RET/PTC was considered to be specific for PTC 
but recent data was found that this rearrangement is expressed  even in some 
non neoplastic conditions such as Hashimoto’s thyroiditis. Several other 
evidences suggest a role for RET/PTC in the association between thyroiditis and 
cancer. In fact, patients exposed to radiation from the Chernobyl nuclear power 
plant disaster often develop not only RET/PTC-induced papillary tumors but 
also an associated autoimmune thyroiditis (Williams et al 2002). Accordingly, 
transgenic mice engineered to express RET/PTC develop papillary carcinomas 
and chronic thyroiditis (Powell et al. 1998). Finally, Wirtschafter and colleagues 
have detected RET/PTC expression in about the 90% of cases of  the 
Hashimoto’s thyroiditis they have analyzed (Wirtschafter et al., 1997). These 
data are, however, partially in contrast with the report by Rhoden and 
colleagues. These authors have found only few follicular cells expressing very 
low levels of the rearranged protein in Hashimoto’s thyroiditis, thus suggesting 
that RET/PTC expression does not necessarily predict the development of a 
papillary carcinoma in patients with thyroiditis (Rhoden et al., 2006). 
 Two hypotheses may explain the  association between Hashimoto’s thyroiditis 
and RET/PTC: 1) the inflammatory favors the occurrence of the rearrangement; 
2) RET/PTC oncoproteins may be directly involved in inducing inflammatory 
responses in thyroid tissues. According to first hypothesis, free radicals 
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production, cytokine secretion, cellular proliferation as well as other phenomena 
correlated with inflammation might predispose to the rearrangement in follicular 
cells (Gandhi et al 2006) .The second hypotesis is supported by the observation 
that RET/PTC3 expressing thyrocytes express high levels of proinflammatory 
cytokines (Melillo et al 2005; Puxeddu et al  2005, Rhoden et al 2006).  
Inflammatory cytokines produced by transformed epithelial cells or infiltrating 
leukocytes are known to positively influence tumor development by affecting 
angiogenesis, growth, survival, immune suppression, DNA damage, tumor 
suppression, and metastasis. In contrast, tumor-infiltrating leukocytes can 
negatively regulate tumor progression by producing cytostatic or cytotoxic 
molecules and induce the death of targeted cells, but the molecular basis for this 
underlying cellular interaction is not well understood. (Mantovani et al 1992; 
Russell et al 2004; Melillo et al., 2005; Puxeddu et al., 2005) In the PTC, 
multiple signaling pathways are required together to work in concert with 
RET/PTC to cause cancer. A major factor is the host’s contribution to the tumor 
microenvironment including angiogenesis, lymphangioenesis, stromal and 
immune reactions. Indeed, despite the overwhelming data to support a role of 
proinflammatory mediators in causing cancer, very little is known about how 
they influence the host microenvironment. Cytokine secretion by transformed 
thyrocytes may play a role in the development and progression of thyroid 
cancer. For instance, low level cytokine production by thyrocytes can directly 
stimulate, in a paracrine or autocrine fashion, the growth of thyroid cells  via the 
secretion of Il1, Il6, or IL4 and IL10 ( Zeki et al 1993; Basolo et al 2002). 
Moreover, previous work has demonstrated that RET/PTC3  can directly induce 
the production of these and other inflammatory factors and, when such cells are 
transplanted into mice, induce the attraction of activated macrophages. These 
and other data suggest that RP3-induced thyroid hyperplasia and carcinoma 
evokes multiple systems in vivo to manifest carcinogenic effects of RET/PTC 
(Russell et al 2003). The consequence of this oncogene-induced cytokine 
secretion is to recruit leukocytes that secrete additional cytokines ( Scarpino  et 
al 2000). Although much is known about the capability of tumors or tumor cells 
to produce proinflammatory mediators at late stages of disease, little is known 
about how these factors may be available early in the process to promote the 
support and progression of transformed epithelial cells.  
Therefore,  the  factor that seems to influence the relationship between thryroid 
cancer and inflammatory infiltration is the “initiating oncogene”, rearrangement 
RET/PTC, that may therefore be critical for promoting tumor progression by the 
activation of specific signaling pathways that not only include those that 
regulate autocrine growth factors or their receptors, but also those that influence 
the immune responses (Russell et al  2006)  Furthermore, the RET/PTC- RAS-
BRAF axis was shown to trigger an up-regulation of CXC chemokines and 
CXC chemokines receptors, which in turn stimulates proliferation and invasion 
(Borrello et al 2005, Puxeddu et al 2005, Melillo et al, 2005) .  
 Chemokines are small chemotactic cytokines that are subdivided into 4 groups 
(CXC, CC, C and CX3C chemokines) on the basis of the relative position of 
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cysteine residues. Chemokines bind to 7-transmembrane G-protein –linked 
receptors. Most tumors produce CXC and CC chemokines  which interact with 
CXCR and CCR respectively. These receptors mediate several biological 
activities (chemotaxis, cytoskeletal rearrangements and adhesion to specific 
cells), triggers a cascade of events that results in activation of AKT and ERK 
and in cell polaritation, adhesion and migration (fig 3). Chemokines regulate 
some important features of cancer cells; moreover  they are also involved in the 
regulation of tumor angiogenesis and leukocyte recruitment  ( Kulbe  H et al 
2004; Kucia et al 2006) 
 
 
 
 
Figure 3. Signal transduction pathways activated by the SDF-1– CXCR4 axis. Interaction of SDF-1 with G-
protein–coupled sevenspan transmembrane receptor CXCR4 activates several pathways in cells, with activation 
varying between cell types. Activation of these pathways in CXCR4+ cells (e.g., normal and malignant stem 
cells) regulates locomotion, chemotaxis, adhesion, and secretion. (Kucia M  et al, Stems Cell 2006) 
 
 
More than 50 different chemokines and 20 different chemokine receptors have 
been cloned. Chemokines usually bind to multiple receptors, and the same 
receptor may bind to more than one chemokine. However, there is one 
exception to this rule: the chemokine stromal-derived factor (SDF)-1, which 
binds exclusively  to CXCR4 and has CXCR4 as its only receptor.  The 
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directional migration of tumor cells to distant organs via lymphatics and blood 
resembles chemokine-directed lymphocyte migration. Recent papers suggest 
(Kulbe et al 2004; Kucia et al 2006) that tumor cells may express restricted and 
specific patterns of chemokine receptors and that responses to chemokine 
gradients may contribute to metastatic spread (fig 4) . The composition of the 
leukocyte infiltrate in many carcinomas is related, in particular, to tumor and 
stromal cell production of CC chemokines ( Liao et al 1989;Rollins et al 1997)  
 
 
 
 
Fig. 4 . Role of chemokines in tumor progression/invasion/outgrowth. (A) Chemokines (stars) produced by tumor 
cells within a solid tumor, attract a leukocyte infiltrate and/or promote proliferation of cancer cells. (B) Cancer cells 
which acquire expression of chemokine receptors may migrate towards a chemokine gradient. Chemokine stimulation 
of receptors may also alter the adhesive capacity of tumor cells. (C) Within a metastatic deposit, chemokine production 
may stimulate tumor growth, but also effect the microenvironment by promoting angiogenesis. ( Kulbe H et al,  Int. J. 
Dev. Biol., 2004) 
 
Chemokines control the directional migration of leukocytes and it seems that 
mechanisms utilised for leukocyte trafficking  may also be used by tumor 
cells. It is described how certain cancer cells can have restricted and specific 
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expression of chemokine receptors, in particular CXCR4 and CCR7 and this 
may be one factor in the development of site specific metastasis. In particular, 
the chemokine receptor CXCR4 and its ligand stromal cell-derived factor-1 
(SDF-1)/CXCL12 appears to be expressed by a majority of cancer types 
including cancers of epithelial, mesenchymal and haematopoeitic origin. This 
fact alone suggests that the SDF-1–CXCR4 axis plays a uniquely important 
biological role and may be involved in tumor cell proliferation and survival, 
as well as in the metastatic capacity of tumor cells ( Bajetto et al 2006, Kucia 
et al 2006, Orimo et al 2005) . 
Recent investigation  has demonstrated a potential role of chemokines and 
their receptor in PTC and in anaplastic thyroid carcinoma (as 
CXCL12,CXCL1, CXCL10, and CXCR4, CXCR2 and CXCR3 receptors 
respectively). These data  have showed  that the RET/PTC rearrangemnt 
(RET/PTC 1 and 3 especially) induces the expression and the up-modulation 
of several inflammatory genes, including chemokines(CXCL12), their 
receptors (CXCR4), cyokines, thus suggesting a possible autocrine loop 
(Castellone et al 2004;  Borrello etal 2005, Hwang et al 2003; De Falco et al 
2007).  
 
 
 
1.3 Staging and Risk Assessment 
 
Conventionally, staging of PTC is based on the pathological results combined 
with the information derived from the post-ablation 131IWBS and from neck 
ultrasound at the moment of ablation ( Mazzaferri et al 1994). Several tumor 
staging systems have been devised to accurately predict a patient’s long-term 
outcome. The first such staging system identified age, sex, cell type (eg, PTC, 
follicular thyroid cancer, etc.), tumor size, and number of metastatic sites as the 
main characteristics in identifying prognosis. Moreover, there are the different  
staging systems (Cady et al 1988;Hay et al 1989; DeGroot et al 1990; Shaha et 
al 1996; Sherman et al 1998; Hay et al 2002). Statistical analyses of staging 
systems show  that the proportion of variance explained averages from about 6% 
to 20% to predict mortality and about 12% to predict the likelihood of a patient 
being disease free. A perfect staging system would predict the correct outcome 
in every patient,  with a proportion of variance explained of  100% (Byar et al 
1979). None of the staging classifications accounts for more than a small 
proportion of the uncertainty in disease specific mortality or the likelihood of 
remaining disease-free over time. The accuracy of predicting outcome with 
these staging systems is thus too low to guide therapy in an individual patient. 
None is superior to the TNM staging system used by most tumor registries, but 
it also has a similarly low proportion of variance explained. The American Joint 
Committee on Cancer/ International Union Against Cancer TNM staging system 
(Hermanek et al. 1992, American Joint Committee on Cancer 2002 and 2005)  
based mainly on the rational that it allows risk stratification to plan the 
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frequency and type of follow up  for individual patients.  The 2002 TNM 
classification is to our knowledge one of the few scoring systems that 
incorporates information regarding the prognostic impact of regional lymph 
node metastases (Tab 1-2). Infact neck lymph node (LN) metastases are found in 
up to 70% of cases of PTC. The presence of neck LN metastases and tumor 
extension beyond the thyroid capsule at diagnosis have been identified as 
indipendent risk factors of recurrence .  
 
 
 
Table 1: The Tumor, Node, Metastases (TNM) scoring system (Hermanek et al. 
1992, American Joint Committee on Cancer 2002 and 2005) 
 
1992 2002 
                                              Primary Tumor (T): 
T0: No evidence of primary tumor No evidence of primary tumor   
T1: Tumor ≤1cm limited to the thyroid Tumor ≤2cm limited to the thyroid 
T2: Tumor>1-≤4cm limited to the thyroid Tumor>2-≤4cm limited to the thyroid 
T3: Tumor>4cm limited to the thyroid Tumor>4cm limited to the thyroid or any 
Tumor with minimal extrathyroid extension 
T4: Any size extending beyond the thyroid 
Capsule. 
T4a: Tumor of any size with extension beyond the  
thyroid capsule and invades any of the following:  
subcutaneous soft tissues,larynx, trachea, oesophagus, 
recurrent laryngeal nerve. 
  T4b: Tumor invades prevertebral fascia, mediastinal 
vessels, or encases carotid artery 
Regional Lymph Node (N): 
 
N0 No regional lymph node metastasis No regional lymph node metastasis 
N1 Regional Lymph Node metastasis Regional Lymph Node metastasis 
 N1a: Metastases in pretracheal and paratracheal,  
including prelaryngeal and delphian lymph nodes 
 N1b: Metastases in other unilateral, bilateral or  
contralateral cervical or upper mediastinal lymph nodes
Distant metastasis (M): 
M0 No distant metastasis    No distant metastasis    
M1 Distant metastasis   Distant metastasis   
 
The 1992 (and 2002) classification system defines 4 stages with increasing risks of cancer-related death 
(Table 3). A comparison of different staging systems evidenced that no other systems had statistically 
significant superiority over the 1992 TNM classification (Hermanek et al. 1992).  
The 2002 TNM classification is more complicated, and the definition of minimal or more extensive 
thyroid tumor extension may be difficult to define retrospectively (Loh 1997).. Six lymph nodes need to 
be examined at histology to qualify for the definition of N0 and the prognostic difference between level 
VI lymph-node metastases and other regional metastases has yet  to be validated.  
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Table 2: TNM Staging (Hermanek et al. 1992, American Joint Committee on 
Cancer 2002 and 2005) 
 
1992 2002 
Age <45 years 
Stage I Any T, any N, M0   Any T, any N, M0   
Stage II Any T, any N, M1   Any T, any N, M1 
Stage III None None 
Stage IV None None 
Age >45 years 
Stage I T1, N0, M0   T1, N0, M0  
Stage II T2-T3, N0, M0 T2, N0, M0 
Stage III T4,N0,M0 or any 
T,N1,M0 
T3, N0, M0 or any  
T1-3, N1a, M0 
Stage IV Any T, any N, M1 None 
Stage IVA: T1-3, N1b, M0 or  
T4a, Any N, M0 
Stage IVB: T4b, Any N, M0 
 
Stage IVC: Any T, Any N, M1 
 
 
 
Recently, in accordance with this system, several attemps to reach consensus 
about treatment of thyroid carcinoma have resulted in guidelines for diagnosis 
and disease management. A European Consensus Report (Pacini et al 2006) 
defined three risk categories for DTC: Very low risk: unifocal T1 (<1 cm) N0 
M0, no extending  beyond the thyroid capsule, and absence of aggressive 
histology (e.g. tall cell, insular, columnar, cell carcinoma) Low risk: T1 (>1 cm) 
or T2 N0 M0 or multifocal T1 N0 M0.  High risk: any T3 and T4 or any T, N1, 
or any M1. In the guidelines stipulated by the American Thyroid Association 
Guidelines (Cooper et al 2006) patients are stratified as follows: Low risk: T1–2 
N0 M0  and absence of aggressive histology or vascular invasion;  Intermediate 
risk: T3 or tumor with aggressive histology or vascular invasion; High risk: T4 
or any T, N1 or M1. (Tab.3)  
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Nevertheless, tumor staging systems are too inaccurate to guide therapy because 
they fail to identify patients with adverse outcomes. A recent study ( Leboulleux 
et al  2006) has demonstrated that the pTNM system is not suitable to assess the 
risk for persistent or recurrent disease. In fact, several important prognostical 
features of thyroid cancer such as the presence of multifocal cancer, vascular 
invasion, autoimmune  thyroid disease in the remaining thyroid tissue and /or 
incomplete surgical resection,  are not included in the TNM staging system. 
Moreover, TNM does not take into account the extent of LN involvement. 
Therefore, the authors proposed that other criteria,such as hystopatological 
subtypes, should be taken into account for the evaluation of prognostic factors 
of survival.  
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2. AIM OF THE STUDY  
 
Although the expression of the chemochine receptor, CXCR4, in 
thyroid carcinoma has been well documented, in contrast the expression 
of its ligand, SDF-1, has not been evaluated in thyroid carcinoma. 
Moreover, the association of these molecules with clinicopathological 
features has not been systematically addressed. 
The purpose of this study was to quantify the expression of these 
molecules in a series of small PTCs and to determine whether their 
expression level  correlates with patient and tumor characteristics.  
This study was of particular interest for several reasons: PTC, including 
small ones, preferentially metastasize to neck lymph-nodes via 
lymphatic stream.  This preferential localization may also depend on the 
repertoire of chemokine receptors expressed on the cell surface of 
cancer cells and, at the end, could  be a potential target for therapeutic 
intervention.  
 
Therefore, the main objectives of my dissertetion were: 
 
• To analyze initial presentation, treatment, outcome and 
prognostic factors according to the TNM classification in patients with 
PTC.  
 
• To evaluate and quantify the expression of inflammatory 
markers as SDF 1- CXCR4 by RT-PCR and immunohistochemistry. 
 
• To determine  whether their expression correlates with  clinical  
and tumor characteristics, indicators of tumor aggressiveness, including 
sex, age, TNM and/or stage, tumor size, focality, extrathyroidal capsule 
extension and  lymph nodes involvement.  
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3. MATERIALS AND METHODS 
 
3.1. Clinical Study 
 
Patients  
 
Clinical charts were retrieved from the archives, according to a list, 
obtained from the central computer system of Institut Gustave Roussy  
(IGR),  of cases treated from the start of their illness at Institut Gustave 
Roussy, Villejuif, between 1996 and 2005. Thyroid tissue samples were 
obtained from the IGR-CRB with informed consent of each patient and 
the approval of the IGR committee.This search  was conducted using 
the terms “thyroid”, “ differentiated carcinoma” and  “papillary 
carcinomas”. According to WHO, the inclusion criteria was: PTC of 
2±1 cm was diagnosed in all patients, histologically , the classic variant 
and  the follicular variant were diagnosed. 
The patients affected by folliculary, medullary, or undifferentiated 
carcinoma were not included in the study.  
For the 48 patients selected ,  histologic hematoxylin and eosin-stained 
slides were reviewed by a single pathologist who was unaware of 
clinical data, in order to confirm the diagnosis. The follicular cell origin 
of the tumors is immunohistochemically confirmed with positive 
thyroglobulin immunoreactivity and no staining for calcitonin.  
For all 48 patients, informations regarding gender, age, tumor size and 
stage, therapy administered and outcomes were collected. Clinical 
parameters including patient age and gender were obtained from 
hospital records. Pathologic parameters , obtained from pathology 
reports, included histologic subtype of papillary carcinoma, tumor size, 
extrathyroidal extension, presence of positive lymph nodes, and 
presence of chronic thyroiditis. 
Stage for PTC was assigned using the TNM system of American Joint 
Committee on Cancer American Joint Committee on Cancer 2002, 
(Hermanek and Sobin 1992, AJCC 2002 and 2005). Follow up data 
regarding recurrences and survival were obtained from the clinical chart 
of IGR. Tumor progression and/or disease recurrence was established 
on the basis of clinical examination and new findings on radiological 
and nuclear scanning. Dates of disease recurrence, newly found 
metastases and death were recorded. The end point was august 2008,or 
loss to follow-up. 
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3.2 Gene Expression Analysis 
 
Tissue Collection and RNA extraction and Reverse Transcription 
Polymerase Chain Reaction (RT-PCR). 
 
Thyroid tumor samples were collected at the time of surgery, snap-
frozen in liquid nitrogen, and stored at -80°C. RNA was extracted from 
frozen tissue by homogenization in RLT lysis buffer (Qiagen, Valencia, 
CA, USA) using the manufacturer’s protocol (RNeasy Mini Kit; 
Qiagen, Valencia, CA, USA). RNA purity was confirmed by 
spectrophotometry.  
Total RNA was isolated by the RNeasy Kit (Qiagen, Crawley, West 
Sussex, UK) and subjected to on-column DNase digestion with the 
RNase-free DNase set (Qiagen) according to the manufacturer’s 
instructions. The quality of RNA was verified by electrophoresis 
through 1% agarose gel and visualized with ethidium bromide. 
Random-primed first strand cDNA was synthesized in a 50 µl reaction 
volume starting from 2 µg RNA by using the GeneAmp RNA PCR 
Core Kit (Applied Biosystems, Warrington, UK). Primers were 
designed by using software available at http://www-
genome.wi.mit.edu/cgi-bin/primer/primer3_www.cgi and synthesized 
by the MWG Biotech (Ebersberg, Germany). To exclude DNA 
contamination, each PCR reaction was also performed on untranscribed 
RNA. 
Quantitative (real-time) reverse transcription polymerase chain 
reactions (QRT-PCR) were performed by using the SYBR Green PCR 
Master mix (Applied Biosystems) in the iCycler apparatus (Bio-Rad, 
Munich, Germany). Amplification reactions (25μl final reaction 
volume) contained 200 nM of each primer, 3 mM MgCl2, 300 μM 
dNTPs, 1x SYBR Green PCR buffer, 0.1U/μl. AmpliTaq Gold DNA 
Polymerase, 0.01U/μl Amp Erase, RNase-free water, and 2 μl cDNA 
samples. Thermal cycling conditions were optimized for each primer 
pair and are available upon request. To verify the absence of 
nonspecific products, 80 cycles of melting curve (55°C for 10 sec) were 
performed. In all cases, the melting curve confirmed that a single 
product was generated. Amplification was monitored by measuring the 
increase in fluorescence caused by the SYBR-Green binding to double-
stranded DNA. Fluorescent threshold values were measured in triplicate 
and fold changes were calculated by the formula: 2-(sample 1 ΔCt - 
sample 2 ΔCt), where ΔCt is the difference between the amplification 
fluorescent thresholds of the mRNA of interest and the ß actin mRNA.  
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3.3 Immunohistochemistry  
 
Methods 
 
All slides were deparaffinized in xylene and rehydrated in a graded 
series of ethanol. To retrieve the antigenicity, the sections were then 
placed in a preheated 10mM citrate buffer (pH 6.0) and heated in 
various conditions. The sections were then immersed in methanol 
containing 0.3% hydrogen peroxidase for 5 min to block the 
endogenous peroxidase activity and were incubated for 30 min with 2.5-
5 % blocking horse serum to reduce nonspecific binding. Sections were 
incubated with primary antibody according to previously validated 
conditions. Following several washes with PBS (phosphate-buffered 
saline), the slides were treated for 30 min with an universal secondary 
biotinylated antibody, then with avidin-biotinylated horseradish 
peroxidase H complex (ABC kit, Vector Laboratories, Burlingame, 
CA). Diaminobenzidine was used as a chromogen (8 min), and 
commercial haematoxylin was used for counterstaining. 
Immunohistochemical analysis (IHC) was performed using the 
BondMax Automated Immunohistochemistry & In Situ Hybridization 
and Bond Polymer Define peroxidase detection systems for CXCR4, 
SDF-1 , (Leica-Vision Biosystems, Melbourne, Australia) . For CXCR4 
the primary antibody was mouse monoclonal IgG2a clone 
12G5(R&DSystems, Minneapolis, MN, USA), while SDF-1 was 
assessed using mouse monoclonal IgG1 clone 79018 (R&D Systems), 
each diluted 1:200 in Bond Primary Antibody After antigen retrieval, 
immunostaining was performed according to the manufacturer’s 
protocol. 
 Positive controls for each antibody  and appropriate negative controls 
lacking primary antibody were performed. Sections were counterstained 
with hematoxylin, dehydrated, and embedded in Cytoseal XYL 
(Richard Allan Scientific, Kalamazoo, MI). Each staining reaction was 
performed in triplicate. 
 
 
 
3.4 Immunohistochemical analysis  
 
The analysis of stained sections was performed with Dr Caillou at 
Institut Gustave Roussy- department of Pathology,. For each patient, all 
spots were analyzed and representative zones were chosen to count 500 
cells. For each marker, a semiquantitative assessment of cytoplasmic 
staining intensity for each antibody  was carried out by two independent 
observers, who assigned a score to each tumor core as follows: 
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1. localization of the marker: in the nucleus, cytoplasm and 
membrane 
2. number of positive cells: we used a score between 1 and 3 (1: 
<50% positive cells, 2: between 50-94% positive cells, 3: between 95-
100% positive cells) 
3. intensity of expression: we used a score between 1 and 3  (1: 
absent or low, 2: moderate, 3: high)  
 
Moreover  for each marker, we evaluated the expression in associated chronic 
thyroiditis and in peritumoral stroma. In particular, when standard histological 
sections of normal tissue, thyroiditis, stroma and tumor specimens were 
carefully examined, several types of epithelial structures were identified:  
1.Normal appearing follicular structures of which the majority of the thyroid  
tissue is usually composed; 
2. Follicles that were more or less damaged by cytotoxic lymphocytes; 
3.Tissue-infiltrating lymphocytes; 
4.Peculiar regenerative metaplastic ductal structures (MDS) which were clearly 
present in thyroiditis samples. They were always found at the periphery of 
organized lymphoid infiltrates to which they are  confined ; 
5.Polinuclear macrophage-like population, fibroblastic-like population;  
6.Papillary differentiated tumoral cells 
7. Epidermoid metaplasia.  
 
 
 
3.5 Statistical Analysis 
 
Data were analyzed using SAS version 8.2 (SAS Inc, Cary, NC). Quantitative 
variables were reported as median (range), and categorical variables as 
absolute numbers and percentages (%).Univariate association of patient clinical 
characteristics with chemoattractant stromal cell-derived factor 1 (SDF-1) and 
chemokine receptor 4 (CXCR4) were tested by means of Kruskal-Wallis exact 
test. Multivariate analyses were performed to evaluate the association of SDF-1 
and CXCR4 with 6 main clinical characteristics included a priori in the model. 
Two different approaches were used. Ordinal logistic regression under a 
proportional odds model was used for categorical dependent variables (DV). If 
the DV has three different ordered categories this approach simultaneously 
models 2 cumulative logits corresponding to using binary cut points at 2 and 3, 
written as log{Pr(DV≥2)/Pr(DV<2)} and log{Pr(DV≥3)/Pr(DV<3)}, 
respectively. Under this proportional odds model, one coefficient is estimated 
for each covariate in the model. The coefficient represents the effect of a one-
unit increase in the predictor variable on the logit (log odds), which is assumed 
to be the same for all two logits. A score test was used to verify the 
proportional odds assumption in the final model. To further verify the 
proportional odds model, we fit binary logistic regressions using DEP cutoffs of 
at least 2 and at least 3, and compared the results with those of the ordinal 
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regressions. Multiple linear regression analysis was used for continuous 
dependent variables. 
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4. Results 
 
 4.1 Patient features 
 
 Forty-eight PTC patients underwent total thyroidectomy and cervical 
lymphnode dissection by a single surgeon at a single institution. 
There were 34 females and  14  males, with a mean age at diagnosis of 
44.0 years [14-80 yrs]. No patient had a family history of thyroid 
carcinoma or of radiation exposure. Chronic thyroiditis was present  in 
29  cases but AbTg and AbTPO was positive in only 2 patients.  
Twenty-five  patients were classified as T1, eleven as T2, and nine as 
T3 and three patients as T4. (Tab 4) The median tumor size was 2± 1 
cm. Lymph-node metastases were present in 31/48 patients. One patient 
had distant metastases at discovery of the disease, in the lung. Twenty-
four  patients showed extracapsule thyroid  extension. (Table 5). 
Median follow-up was 6.1 years, during which 9 patients developed 
metastases : lymph nodes metastases  occurred in  the central 
compartment in 7 patients, mediastinal region in one patient and in both 
neck lymph nodes and lungs in another patient. Lymph-nodes 
metastases occurred in patients aged less than 45 years while distant 
metsatses occurred in patients older than 45 years. Among the 9 patients 
with metastases, 5 had a microcarcinoma at the time of diagnosis and  4 
had a primary tumor _> 2cm. Eigth patients (including all patients with 
distant metastases) showed an extension beyond the thyroid capsule and 
all of these had lymph nodes metastases at the time of diagnosis. We did 
not find a correlation between the appearance of metastases and the 
presence of thyroiditis in any case. The data of recurrent disease was 
noted but the parameters were excluded from analysis due to their small 
numbers.  
Radioiodine uptake was present in metastases on radioiodine (131I) 
whole body scan performed 3 to 5 days after the administration of 
3.7GBq in all of the 10 patients with recurrent diseases who were 
treated with radioiodine. In all patients clinical benefits were observed 
after treatment with radioiodine. In fact, no patient with  metastases 
died after a mean follow-up of  3.1 years after initial treatment.  
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Table 4: Clinical  characteristics in 48 patients with PTC  
Clinical characteristics 
Age   
≤ 45 26 
> 45 22 
Gender  
M 14 
F 34 
Stage  
Stages 1,2 32 
Stages 3,4 16 
Thyroiditis  
Absent 19 
Present 29 
 
 
 
 
Table 5: Tumor characteristics in 48 patients with PTC  
tumor characteristics 
Histotype variant   
Classic 27 
Follicular  21 
Focality  
Unifocal 34 
Multifocal 14 
Extracapsule thyroid extension   
Absent 24 
Present 24 
Dimension  
< 2cm 26 
>2 cm 22 
Lymph Nodes (TNM)**  
Absent 17 
Present 31 
T (TNM)*  
T1 25 
T2 11 
T3 9 
T4 3 
 
* One missing value for tumor size.      
**One missing value for lymph nodes metastases  
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4.2 CXCR4 and SDF 1 mRNA expression 
 
Each  tumoral tissue sample was analyzed for CXCR4 and SDF 1 gene 
expression by Real Time -PCR . In all cases, CXCR4 and SDF-1  were found 
to be up regulated in tumor samples vs samples of  normal thyroid tissue  
The chi-square test showed a highly significant association between CXCR4 
and SDF-1 expression (p<0.05), indicating  a tendency  toward  co-expression 
of these markers in a subset of tumors.   
 
 
 
4.3 CXCR4 and SDF 1 localization by Immunohistochemistry.  
 
IHC analysis was performed to confirm the data obtained in the RTPCR 
experiments at the protein level and to determine the cell type that actually 
expresses CXCR4 and SDF-1 in the tumor site, in peritumoral stroma, in 
normal tissues and in  associated chronic thyroiditis.    
In accordance with RT -PCR,  all tumoral tissues investigated expressed  SDF-
1 with high intensity and with a percentage of positive cells of < 50% in 5, of 
50-94% in 25, and  of 95-100% in 18 tumors. A diffuse citoplasmic expression 
was found both in papillar tumor cells and in epidermoid metaplasia (figure 5 ) 
 
 
 
Fig 5  Immunohistochemical analysis for SDF-1 (formalin-fixed, paraffin-embedded thyroid 
carcinoma) : SDF-1 expression in human papillary  thyord cancer: localization of SDF  protein was 
cytoplasmic in papillary differentiated structures (1) and in epidermoid metaplasia (2). 
We have also found that SDF-1 is abundantly expressed by peritumoral stromal 
tissues, but with moderate-low intensity. In particular we observed that the 
subset of fibroblast-like cells, especially were positive for SDF-1 (as indicated 
A
B
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by figure 6), with a percentage of positive cells of >50% in 42 cases. In 
contrast, we failed to detect any fibroblastic –like cells  positive for SDF-1 in 
non cancer stroma. Moreover  we detected  SDF-1 expression to some extent in 
scartered normal epithelial cells and endothelial cells (figure 7).  
 
 
 
 
 
 
Fig 6 : Immunohistochemical analysis for SDF-1 (formalin-fixed, paraffin-embedded thyroid 
carcinoma): Fibroblast-like cells  (thyn arrows) located between the papillary structures  moderatly 
expressed  SDF-1,  while  epidermoid  metaplasia  was strogly SDF-1 positive (thyck arrow) 
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Fig 7 Immunohistochemical analysis for SDF-1 (formalin-fixed, paraffin-embedded thyroid 
carcinoma): PTC expressed  SDF-1 with high intensity (red arrow), whereas normal follicules were  
faible SDF-1 positive (thyn arrows). 
 
Finally, we have found a characteristic SDF-1 expression in chronic thyroiditis. 
In particular, we have found a peculiar distribution SDF-1 staining in the  
metaplastic/hyperplastic ductal structures (MSD) localized at the periphery of 
organized lymphoid infiltrates, which, on the contrary, appeared  widely 
negative for SDF-1 (figure 8).   
 
 
 
 32
 
 
Fig 8 Immunostaining for SDF-1 in chronic thyroiditis shows  that MDS (red arrows) are 
specifically located at the periphery of lymphoid follicles and strongly expressed SDF-1. 
Lymphocytes  were SDF-1 negative (thin arrow). 
 
 
We then evaluated the expression levels of SDF-1 receptor, CXCR4, in the 
same PTC tumors. All tumors expressed CXCR4, but with heterogenous 
intensity (low, moderate and high in 15, 16 and 17 patients respectively) and 
with a percentage of positive cells of  50-94% in 26 and of 95-100% in 22 
cases. CXCR 4 is a membrane receptor.Despite this, in cancer positive cells, 
CXCR4 staining was located into cytosolic granules. Since this receptor 
undergoes rapid internalization upon ligand binding (figure 9).This pattern of 
expression can be explained by receptor down-regulation. Whatever the case, 
these data indicate that a significant fraction of PTC, similarly to other 
ephitelial cancers, features high expression levels of the CXCR4.  
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Fig 9 CXCR4 expression in human papillary thyroid carcinoma tissue (hematoxylin-eosin-stained 
paraffin-embedded tumor sections):  immunohistochemical localization of CXCR4 protein was 
cytoplasmic. Typical granular aspect.   
 
 
The distribution of CXCR4 in the peritumoral stroma seems completely 
different from that of its ligand SDF-1. As shown  in  figures 10 and 11, 
CXCR4 is expressed only in stromal-derived cells, particularly  in 
macrophage-like  cells and lymphocytes cells, with  a percentage of positive 
cells of < 50% in 13 cases, of 50-94% in 23, and of 95-100% in 11 with 
variabile intensity. In some cases, stromal cells showed positive staining in the 
nucleus in addition to cytoplasmic staining and an expression in granular form 
were found in all cases.  
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Fig 10 and 11: CXCR4 in peritumoral stroma tissuse: fibroblastic and macrophage-like cells were 
strongly positive for CXCR4.   
 
 
In the chronic thyroiditis, in contrast to what observed for SDF-1, CXCR4 was 
shown to be expressed at significantly higher amounts in lymphocyte 
populations and not in peripheral MDS (Fig 12) 
Finally, peritumoral normal thyroid tissue displayed a lower but detectable 
expression. This reactivity was localized to follicular thyroid cells, stromal 
cells or infiltrating lymphocytes. (Fig 13). 
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Fig 12. HCI staining  for CXCR4  occurred  in  chronic thyroiditis: intense expression of 
CXCR4  in the lymphocytes cells 
 
 
 
 
Fig 13: In some cases  normal activated  stromal cells shoed positive staining for CXCR4  in the 
cytoplasm   
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4.4 Correlations between SDF-1/CXCR4expression  and clinico and tumor–
pathological factors. 
 
In this study, no significant correlation were found between the levels of SDF-
1 and CXCR4 mRNA  and tumoral  and clinical subgroups (Tab.6-7).  
For immunohistochemical staining, we have compared the intensity score and 
the percentage of SDF-1 and CXCR4 positive cells with clinical and tumoral 
characteristics, indicators of tumor aggressiveness.  
We found no significant association of SDF-1 or CXCR4 staining intensity or 
percentage  with  any of  the patient characteristics evaluated Moreover, we 
found a significant association between the SDF-1 and female gender(p ═ 
0.05), (Table 8), this association was not shown following multivariate 
analyses.  
Among tumor features, CXCR4 immunostaining positivity was significantly 
higher in classical variant relative to follicular variant ( p═0.02). The  intense 
staining for CXCR4 was also associated with a smaller tumor size (p═ 
0.03),(Tab 9). These association were confirmed  also when  CXCR4 positivity 
was expressed  through percentage of positive cells  ( p═0.0045) (Tab 10). 
Higer CXCR4 expression (Tab. 9) was found among tumors showing  lymph-
node involvement (N1) at the initial diagnosis (p═0.01). No significant  
association with multifocality,  or extrathyroidal extension was observed.   
Moreover, tumor features were not significantly associated with SDF-1 
expression.  
Finally, a multivariate analysis, corrected for known predictors of recurrence,    
confirmed  the CXCR4  univariate  results.  (table 11-12-13).  
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Table 6: Correlation between real time RTPCRCXCR4 expression and 
                 clinical/tumoral factors – univariate analisys 
 
 
 
 
 
 
 
 
 
 
 
 
   
RTPCRCXCR4  
 
 N Median Minimum Maximum p 
Age 
   
    ≤ 45 26 4.55 0.38 39.4 NS 
    > 45 22 4.92 1.21 34.3  
Gender 
     
     F 34 4.38 0.38 39.4 NS 
     M 14 4.92 1.21 22.16  
Stage  
     
    I 31 3.73 0.38 39.4 NS 
    II 1 3.03 3.03 3.03  
    III 8 5.29 1.21 24.25  
    IV A 8 8.57 4.92 34.3  
Thyroiditis 
     
    Absent 19 4.92 0.38 39.4 NS 
    Present 29 5.66 1.23 34.3  
Histotipe  
     
    Classic 27 4.92 0.38 39.4 NS 
    Follicular 21 4.6 1.21 34.3  
Focality 
     
    Unifocal 34 4.92 0.38 39.4 NS 
    Multifocal 14 4.97 1.52 52.99  
Extrathyroid extension      
     Absent 24 3.45 1.23 39.4 NS 
     Present 24 5.66 0.38 34.3  
Dimension 
     
     < 2 cm 26 4.92 1.39 39.4 NS 
     > 2cm 22 4.92 0.38 34.3  
Lymph Nodes TNM      
     Absent 17 3.41 1.39 34.3 NS 
     Present 31 5.66 0.38 39.4  
T (TNM) 
     
     T1 25 4.87 1.39 39.4 NS 
     T2 11 3.25 1.21 22.11  
     T3 9 6.96 0.38 22.16  
     T4 3 14.62 3.03 34.3  
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Table 7: Correlation between real time RTPCRSDF-1 expression and 
                 clinical/tumoral factors – univariate analisys 
 
 
   
RTPCRSDF-1  
 
 N Median Minimum Maximum p 
Age 
   
    ≤ 45 26 5.29 1.6 22.63 NS 
    > 45 22 5.39 0.2 21.1  
Gender 
     
     F 34 4.01 0.2 22.63 NS 
     M 14 7.25 1.9 16  
Stage  
     
    I 31 5.68 1.6 22.63 NS 
    II 1 2 2 2  
    III 8 6.5 0.2 12.13  
    IV A 8 3.62 1.9 21.1  
Thyroiditis 
     
    Absent 19 4.92 1.86 19.69 NS 
    Present 29 5.66 0.2 22.63  
Histotipe  
     
    Classic 27 4.93 1.6 22.63 NS 
    Follicular 21 5.65 0.2 21.1  
Focality 
     
    Unifocal 34 4.6 1.6 22.63 NS 
    Multifocal 14 6.07 0.2 16  
Extrathyroid extension      
     Absent 24 5.68 1.6 22.63 NS 
     Present 24 3.62 0.2 22.1  
Dimension 
     
     < 2 cm 26 5.29 0.2 22.63 NS 
     > 2cm 22 5.11 1.6 13.9  
Lymph Nodes TNM      
     Absent 17 11.46 0.2 21.11 NS 
     Present 31 3.89 1.6 22.63  
T (TNM) 
     
     T1 25 5.65 1.62 22.63 NS 
     T2 11 6.5 1.6 16  
     T3 9 3.2 0.2 13.9  
     T4 3 2.87 2 3.73  
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Table 8: Correlation between immunoistochemical staining of SDF-1               
(number of positive cells) expression and clinical/tumoral factors -          
univariate analisys
  
SDF-1 Numbers of positive cells  
 
  2 3  
 N Mean intensity z score (%) Univariate p value 
Age 
    
    ≤ 45 26 12(48%) 9 (50%) NS 
    > 45 22 13(50%) 9 (50%)  
Gender 
    
     F 34 15(60%) 16(89%) 0.05 
     M 14 10(40%) 2 (11%)  
Stage  
    
    I 31 15(60%) 12 67%) NS 
    II 1 0 (0%) 0 (0%)  
    III 8 4 (16%) 4 (22%)  
    IV A 8 6 (24%) 3 (11%)  
Thyroiditis 
    
    Absent 19 10(40%) 6 (33%) NS 
    Present 29 15(60%) 12 67%)  
Histotipe  
    
    Classic 27 16(64%) 9 (50%) NS 
    Follicular 21 9 (36%) 9 (50%)  
Focality 
    
    Unifocal 34 20(80%) 11(61%) NS 
    Multifocal 14 5 (20%) 7 (39%)  
Extrathyroid extension     
     Absent 24 14(56%) 8 (44%) NS 
     Present 24 11 44%) 10(56%)  
Dimension 
    
     < 2 cm 26 10(40%) 12(67%) NS 
     > 2cm 22 15(60%) 6 (33%)  
Lymph Nodes (TNM)      
     Absent 17 9 (36%) 7 (39%) NS 
     Present 31 16(64%) 11(61%)  
T (TNM) 
    
     T1 25 12(48%) 10 55%) NS 
     T2 11 10(40%) 1 (6%)  
     T3 9 2 (80%) 6 (33%)  
     T4 3 1 (4%) 1 (6%)  
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Table 9: Correlation between immunoistochemical staining of CXCR4 
(intensity) expression and clinical/tumoral factors – univariate analisys 
 
   
CXCR4  
 
  Low intensity Medium intensity High intensity  
 N Mean intensity z score (%) Univariate p value 
Age 
     
    ≤ 45 26 7 (47%) 12 (75%) 7 (41%) NS 
    > 45 22 8 (53%) 4 (25%) 10 (59%)  
Gender 
     
     F 34 11 (73%) 10 (62%) 13 (76%) NS 
     M 14 4 (27%) 6 (38%) 4 (24%)  
Stage  
     
    I 31 10 (67%) 12 (75%) 9 (52%) NS 
    II 1 1 (7%) 0 (0%) 0 (0%)  
    III 8 2 (13%) 2 (12.5%) 4 (23.5)  
    IV A 8 2 (13%) 2 (12.5%) 4 (23.5)  
Thyroiditis 
     
    Absent 19 4 (27%) 7 (44%) 8 (47%) NS 
    Present 29 11 (73%) 9 (56%) 9 (53%)  
Histotipe  
     
    Classic 27 4 (27%) 11 (69%) 12 (70%) 0.02 
    Follicular 21 11 (73%) 5 (31%) 5 (30%)  
Focality 
     
    Unifocal 34 10 (67%) 12 (75%) 12 (71%) NS 
    Multifocal 14 5 (33%) 4 (25%) 5 (29%)  
Extrathyroid extension      
     Absent 24 8 (53%) 10 (63%) 6 (35%) NS 
     Present 24 7 (47%) 6 (37%) 11 (65%)  
Dimension 
     
     < 2 cm 26 10 (67%) 9 (56%) 7 (41%) NS 
     > 2cm 22 5 (33%) 7 (44%) 10 (59%)  
Lymph Nodes TNM      
     Absent 17 8 (53%) 7 (44%) 2 (12%) 0.01 
     Present 31 7 (47%) 9 (56%) 15 (88%)  
T (TNM) 
     
     T1 25 11 (74%) 6 (37.5%) 8 (47%) 0.03 
     T2 11 2 (13%) 6 (37.5%) 3 (18%)  
     T3 9 0 (0%) 3 (19%) 6 (35%)  
     T4 3 2 (13%) 1 (6%) 0 (0%)  
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Table 10: Correlation between immunoistochemical staining of CXCR4 
(Numbers of tumor cells) expression and clinical/tumoral factors – 
univariate analisys 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
CXCR4 Numbers of 
tumor cells  
 
  2 3  
     
 N Mean intensity z score (%) Univariate p 
value 
Age 
    
    ≤ 45 26 13 (50%) 13 (59%) NS 
    > 45 22 13 (50%) 9 (41%)  
Gender 
    
     F 34 21 (81%) 13 (60%) NS 
     M 14 5 (19%) 9 (40%)  
Stage  
    
    I 31 16 (62%) 15 (68%) NS 
    II 1 1 (4%) 0 (0%)  
    III 8 4 (15%) 4 (18%)  
    IV A 8 5 (19%) 3 (14%)  
Thyroiditis 
    
    Absent 19 9 (35%) 10 (45%) NS 
    Present 29 17 (65%) 12 (55%)  
Histotipe  
    
    Classic 27 14 (54%) 13 (59%) 0.02 
    Follicular 21 12 (46%) 9 (41%)  
Focality 
    
    Unifocal 24 14 (54%) 10 (45%) NS 
    Multifocal 24 12 (46%) 12 (55%)  
Extrathyroid 
extension 
    
     Absent 24 10 (63%) 6 (35%) NS 
     Present 24 6 (37%) 11 (65%)  
Dimension 
    
     < 2 cm 26 17 (65%) 9 (41%) NS 
     > 2cm 22 9 (35%) 13 (59%)  
Lymph Nodes 
(TNM) 
    
     Absent 17 9 (34%) 8 (37%) NS 
     Present 31 17 (66%) 14 (63%)  
T (TNM) 
    
     T1 25 19 (73%) 6 (27%) 0.0045 
     T2 11 3 (11%) 8 (36%)  
     T3 9 2 (8%) 7 (32%)  
     T4 3 2 (8%) 1 (5%)  
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Multivariate proportional odds regression model 
 
    Table11 
 
CXCR4 intensity OR 95% CI p-value 
Sex, M vs F 0.58 0.15 2.19 0.417 
age, >=45 vs <45 1.88 0.54 6.61 0.325 
T, T3-T4 vs T1 2.68 0.56 12.77 
T, T2 vs T1 1.10 0.25 4.86 
0.441 
N, N1 vs N0 3.75 1.00 13.96 0.049 
Histology, yes vs no 0.13 0.04 0.49 0.003 
Thyroiditis, yes vs no 0.49 0.14 1.69 0.258 
     
     
 
Table 12 
 
CXCR4 Numbers of 
tumor cells OR 95% CI p-value 
Sex, M vs F 3.66 0.70 19.25 0.126 
age, >=45 vs <45 0.45 0.10 2.16 0.321 
T, T3-T4 vs T1 16.17 2.19 119.17 
T, T2 vs T1 14.98 1.92 117.15 
0.009 
N, N1 vs N0 0.22 0.04 1.31 0.096 
Histology, yes vs no 0.78 0.18 3.50 0.749 
Thyroiditis, yes vs no 0.85 0.19 3.90 0.838 
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Table 13 
 
SDF-1 Numbers of 
tumor cells OR 95% CI p-value 
Sex, M vs F 0.26 0.07 1.02 0.053 
age, >=45 vs <45 2.29 0.67 7.86 0.188 
T, T3-T4 vs T1 2.09 0.44 9.91 
T, T2 vs T1 0.83 0.18 3.77 
0.546 
N, N1 vs N0 0.71 0.19 2.62 0.611 
Histology, yes vs no 0.78 0.23 2.59 0.683 
Thyroiditis, yes vs no 1.60 0.47 5.48 0.454 
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5. Discussion  
 
Chemokine receptors are transmembrane proteins that interact with specific 
chemokine ligands, resulting in G-protein-coupled signal transduction, which  
lead to chemotaxis (a directional movement along a chemical gradient). 
Chemokine receptors play an important role in many physiological processes, 
including normal migration of precursor cells during the development and 
targeting leukocytes to sites of inflammation. Functional chemokine receptors 
have been shown to be expressed by a large number of human malignancies, 
leading to the hypothesis that chemokines may stimulate proliferation, 
chemotaxis, and site-directed metastasis of tumor cells (Muller et al 
2001;Burger et al 2003; Hwang et al 2003; Kucia et al 2006). Recently, the 
literature data have reported that  the chemokine receptor is expressed in 
papillary and anaplastic thyroid carcinomas (Castellone et al 2004; Hwang et al 
2003; Melillo et al 2005;De Falco et al 2007). In particular, the majority of 
research has been focused  on the CXCR4 receptor. The CXCR4 receptor 
interacts specifically with its chemokine ligand, SDF-1, to exert proliferative 
anti-apoptotic and chemotactic effects in CXCR4-expressing cancer cells 
(Kucia et al 2004). In several human tumors, including carcinomas of the lung, 
breast, prostate, and colon, an association between CXCR4 and the ability of 
metastasis and survival has been found (Salvucci et al 2006;Spano et al 2004; 
Su et al 2005). Recently, CXCR4, which is not expressed at valuable levels in 
normal thyrocytes, has been detected in papillary and anaplastic thyroid 
carcinoma cell lines that undergo chemotaxis in response to the chemokine 
SDF-1 (Castellone et al 2004;Hwang et al 2003). Moreover, CXCR4 is 
upregulated in normal rat and human thyrocytes transformed with the 
RET/PTC oncogene, resulting in increased proliferation, survival, and 
migration in vitro in response to SDF-1 (Basolo et al 2002;Borrello et al 2005 ; 
Castellone et al 2004) .   
In the present study, we analyzed the expression of CXCR4 and SDF-1 in 48 
PTC specimens and their use as  molecular markers that predict tumor outcome 
in low risk patients. These tumors are considered low risk on the basis of  
tumor size (2±1cm) and histological types (classical or follicular variant) of 
PTC. Moreover, we found that the chronic lymphocytic thyroiditis  was present 
in 60% of cases, but we found no association between the presence of 
inflammation and the degree of chemokine or chemokine receptor expression 
by malignant epithelial cells. 
We confirmed that CXCR4 is significantly expressed in PTC, but with a 
particular and different distribution in tumoral and peritumoral tissues. 
Although CXCR4 is a membrane receptor, we found it expressed in cytosolic 
granules in our tumor cells. This result could be explained by receptor down 
regulation after rapid internalization with its ligand.   
In peritumoral stroma, we observed higher CXCR4 positivity, especially in 
macrophage-like cells and in lymphocytes. We also found significantly higher  
amounts of CXCR4 in lymphocyte populations in associated tumoral chronic 
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thyroiditis. Therefore, this finding leads us to believe that  CXCR4 could be 
involved in the maintenance of inflammatory infiltrate. Moreover, this data 
suggest that this receptor may mediate  the attraction of leukocytes that interact 
with nascent cancer and form the tumor stroma. The notion that early stages of 
cancer are dependent on the host (via interaction with leukocytes) has been 
previously established and more recently shown through animal models. 
Likewise, in studies of methylcholanthrene-induced carcinomas, the role of 
host leukocytes, which  cause a paradoxical supporting rather than inhibiting, 
was referred to as a “lymphodependent” stage of cancer (Balkwill et al 2001; 
Balkwill et al 2004, Russell et al 2004) .  
Little is known about the role and expression of SDF-1 in PTC. Several authors 
have demonstrated that the fibroblast within invasive carcinomas contribute to 
tumor promotion through the secretion of SDF-1 in solid tumors( Orimo et al 
2005; Bajetto et al 2006). Our results are the first to demonstrate by real time 
RTPCR and IHC that   SDF-1 is abundantly expressed in papillary carcinoma 
cells other than in fibroblasts. Therefore, contrary to previous findings, this 
evidence suggests that not only thyroid tumoral stroma is a source of 
chemokines in PTC, but more importantly, cancer cells are the main sourse of 
SDF-1. This supports the concept that SDF 1 is pivotal in sustaining local pro-
tumorigenesis events, such as growth and survival of cancer cells. (Orimo et al 
2005). Furthermore, the expression of SDF-1 by stromal cancer cells can 
recruit endothelial progenitors for tumor angiogenesis. (Burger et al  2006).  
In the presence of chronic thyroiditis, we found a different SDF-1distribution  
compared to CXCR4. Using immunohistochemical analysis, we demonstrated 
that  SDF-1 is clearly overexpressed in MDS. Caillou has demonstrated that 
lymphocytic autoimmune thyroiditis displays ductal- like structures defined as 
ductal metaplasia, responsible for chronic inflammatory injury. It has been 
described that c-Kit, BcL2, HBME, EGFR, vimentin, galectin 3 are positively 
expressd in this peripheral thyroiditis region. These proteins are often negative 
in normal thyrocytes but they are usually present in PTCs, correlating with  
survival, migration and  antiapoptotic events  
Moreover, the expression of RET/PTC oncogenes in autoimmune diseases 
provides a close link between  the inflammation and the pathophysiology of the 
cancer (Rodhen et al 2006). Together, these data suggest that the 
microenvironment of thyroid cancer may be modeled as a complex mixture of 
resident thyroid epithelial cells, producing chemokines that induce the 
infiltration of inflammatory cells, (including activated macrophages) that 
respond to these mediators and secrete additional factors (Melillo et al 2006). 
The interplay between the inflammatory mediators produced by the organ and 
those produced by the responding inflammatory cells may accelerate tumor 
progression by promoting angiogenesis and encouraging tumor cell growth 
through induction of antiapoptotic proteins or soluble growth factors .  
Since we observed the co-expression  of both SDF-1 and its receptor in the 
early PTC stage, the occurrence of an autocrine /paracrine loop can be 
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hypothesized as an early event in  PTC, providing a proliferative advantage for 
SDF-1 sensitive cells.  
We hypothesize that the expression of CXCR4 and SDF-1 in low risk papillary 
thyroid carcinoma would correlate with clinicopathological indicators of tumor 
progression. We found that CXCR4 expression is significantly associated with 
a smaller tumor size (T1 vs T2,T3 and T4). This result is the first to show this 
association. This could indicate  that the chemokines  can be expressed early in 
PTC tumorigenesis. The production of both CXCR4 and SDF-1 provides an 
autocrine stimulus for the proliferation and metastasis, thus giving an 
aggressive subset of microPTCs. Interestingly, we observed that classical 
variant PTC cells express more CXCR4  than follicular subtypes of PTC. We 
can speculate that the observed differences in CXCR4 expression may reflect 
underlying molecular alterations of follicular variant PTC, such as a higher 
frequency of RAS mutations (Fagin et al 1993) and a lower prevalence of 
RET/PTC  and BRAF mutations  (Leboeuf et al 2008; Frattini et al 2004) 
relative to classical PTC (in our cases we found V600E point mutation BRAF 
in 50% of cases, data not shown).  Moreover, we found a correlation between 
CXCR4 expression and lymphnode involvement at the initial diagnosis. 
Considering the generally accepted concept that lymph node metastases are 
independent negative prognostic factors (Leboulleux et al 2006), it appears 
logical that this correlation was found to be associated with a poor prognosis. 
 Finally, we found an association (p ═ 0.059) between the SDF-1 and female 
gender, but other studies are necessary to confirm a correlation between 
genotype and phenotype in PTC.  
The present study did not find any differences in tumor multifocality  and 
extracapsule thyroid extension with  CXCR4 or SDF-1 expression in tumor 
tissue. The relatively small number of tumors studied may have reduced our 
power to detect differences among tumor subgroups. Therefore, no correlation 
was  found between CXCR4 and SDF-1 mRNA expression and , it is possible 
that post-transcriptional regulation may be responsible for the observed 
differences in chemokine receptor protein levels. In addition, the presence of 
inflammatory and stromal cells in thyroid tissue could confound gene 
expression analysis, since these cells are likely to contain mRNA for 
chemokines and chemokine receptors, but should not confound IHC analysis 
in tumor cells which were evaluated for staining intensity and positive cell 
percentage. 
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Conclusion:  
 
 In the past years, the increasing incidence of  small  PTCs  are correlated to 
early diagnosis. However, not all small  PTCs are entirely innocuous; therefore, 
it is crucial to detect markers for aggressive PTC subtypes at the initial 
diagnosis. The major findings of our study show that:  
• CXCR4 is significantly expressed in PTC, confirming previous 
literature. However, there is a particular and different distribution in 
tumoral and peritumoral tissues.  
• SDF-1 is abundantly expressed in papillary carcinoma cells other than 
in fibroblasts. This data is a first to demonstrate that the thyroid cancer 
cells are the main sourse of SDF-1. This supports the concept that 
SDF- 1 is pivotal in sustaining local pro-tumorigenesis events, such as 
growth and survival of cancer cells. 
 Moreover, in this study we found a significant  co-expression  of both SDF-1 
and its receptor CXCR4, in the early PTC stage. The occurrence of this  
autocrine /paracrine loop can provide a proliferative advantage for SDF-1 
sensitive cells. In fact CXCR4 is significantly associated with initial 
lymphnode involvement , thus giving an aggressive subset of  small PTCs . 
Future studies in larger sets of patients will be necessary to determine the 
utility of these molecules as biomarkers of aggressive PTC. Novel therapeutic 
strategies designed to manipulate the activity of chemokines and their receptors 
could have efficacy in PTC and other common epithelial malignancies that 
exploit CXCR4 and SDF-1 during the processes of tumor progression and 
metastasis.  
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